5th Annual CNPN Symposium


A-H    |    K-0     |     P-Z                [PDF-print all]


Paul Keown, University of British Columbia.
Dr. Keown is a Professor of Medicine and Director of Immunology at the University of British Columbia. His research targets the immune response in transplantation and autoimmune disease, ranging from molecular genetics to clinical immunotherapeutics. He has been a leader in numerous international societies and research organizations including President of the Canadian Transplantation Society, President of the XXIII International Transplant Congress, and Chair of the Canadian Chromosome-6 Consortium of HUPO.
Abstract: The Canadian Chromosome 6 Consortium: Integrating chromosome-centric and biology/disease driven strategies

Liang Li

Liang Li, University of Alberta.
Dr. Li is a Professor of Chemistry, Adjunct Professor of Biochemistry, and Tier 1 Canada Research Chair in Analytical Chemistry in the Department of Chemistry at the U niversity of Alberta. His research interest is in the area of developing analytical mass spectrometry for biomolecule and polymer analysis, including proteomics and metabolomics applications. He has won several awards including the Rutherford Memorial Medal in Chemistry from the Royal Society of Canada (2003), the F.P. Lossing Award from the Canadian Society for Mass Spectrometry (2006), the Maxxam Award from the Canadian Society of Chemistry (2009), and the Gerhard Herzberg Award from the Canadian Society for Analytical Sciences and Spectroscopy (2010).
Abstract: Shotgun Protein Sequencing by Mass Spectrometry


Thierry Meinnel, CNRS Centre de Recherche de Gif, France.
Dr. Meinnel's research deals with the understanding of the function of early cotranslational protein modifications. Such modifications affect the N-termini of most proteins before folding on a nascent polypeptide chain while it is still attached on the ribosome. The approach of the laboratory combines genetics, structural biology, proteomics, cell biology, bioinformatics, chemistry, and biochemistry to get a full biological picture of this crucial process and propose therapeutic targets and small molecules to fight various diseases including cancer and infectious diseases.
Abstract: Protein N-terminal Modifications at the Proteome Scale and their Impact on Cell Functions


Robert Moritz, Institute for Systems Biology, Seattle.
Dr. Moritz is an Associate Professor and Head of Proteomics Research at the prestigious ISB. He is an extremely experienced and productive researcher with 30 years of experience in protein discovery and elucidation of protein structure and function. With 180 publications to date, he has pioneered microscale proteomics and continues to develop new quantitative technologies that revolutionize protein identification and quantitation. His recent efforts in targeted quantitative technology development has culminated in the completion of the largest collection of molecular assays for essentially every human protein, a first time effort in the identification if every known human protein.
Abstract: Whole Proteome Resources for SRM assay development


Tommy Nilsson, McGill University, Montreal.
Dr. Nilsson is a Professor of Medicine and holds a Tier 1 Canada Research Chair in Proteomics & Systems Medicine. He is also the Director of the Proteomics McGill University and the Research Institute of the McGill University Health Centre (RI-MUHC). His primary research interest is in the cell biology and pathophysiology of fatty liver disease and type 2 diabetes. He joined McGill University and the RI-MUHC in 2009 leaving his Professor position at the Sahlgrenska Academy at Gothenburg University, Sweden. Between 1995 and 2003, Nilsson was group leader at the European Molecular Biology Laboratory in Heidelberg, Germany. His postdoctoral studies were at Cancer Research UK in London and his doctoral studies were at the Scripps Clinic & Research Foundation, La Jolla and Uppsala University, Sweden.
Abstract: Non-Alcoholic Fatty Liver Disease through Proteomics: A Chronic Disease of the 21st Century


Gilbert Omenn, University of Michigan.
Dr. Gil Omenn is Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan. His research is focused on cancer proteomics, bioinformatics, and splice variants of RNA and proteins. He is chair of the global Human Proteome Project, member of the HUPO Executive Committee, and past president of US HUPO. He is a past president of the American Association for the Advancement of Science and a member of the Institute of Medicine of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, the board of directors of Amgen Inc., and the Scientific Management Review Board for the National Institutes of Health.
Abstract: Splice Variant Proteins as a New Class of Cancer Biomarker Candidates & Overview of the Strategy, Organization, and Progress of the HUPO global Human Proteome Project


Christopher Overall, University of British Columbia.
Dr. Overall is a Professor and Tier 1 Canada Research Chair in Metalloproteinase Proteomics and Systems Biology at the University of British Columbia, Centre for Blood Research. He is currently an External Senior Fellow, Freiburg Institute for Advanced Studies - FRIAS, Albert-Ludwigs-Universität Freiburg. Dr. Overall won the Institute of Musculoskeletal Health and Arthritis CIHR Award as 2002 CIHR Scientist of the Year, the University of British Columbia Killam Senior Researcher Award (Science) 2005, and was the Chair of the 2003 Matrix Metalloproteinase Gordon Research Conference and the 2010 Protease Gordon Research Conference. With over 10,500 citations for his 195 papers and with an h factor of 58 he is a highly influential scientist in the field. Professor Overall is the pioneer of degradomics, indeed he coined this term. With 6 Nature Review papers on this and drug target validation and with numerous protease degradomics approaches published in Nature Journals he is a leader in the field that was recently recognized by the International Society of Proteolysis with a Lifetime Achievement Award in October 2011 and by Matrix Biology Society of Australia and New Zealand with the 2012 Barry Preston Award.
Abstract:Terminomics Identifies New Inflammatory Pathways Under Proteolytic Regulation in vivo

2013 Sponsors
Genome BC M.Smith C M Genome PQ K-Prime MRM HUPO NEB AB Sciex Bruker B S I Thermo Agilent BCPN Uvic PC Genome Canada